G. Ruffolo, G. Perugi - Vol. 8, March 2002, Issue 1
Testo Immagini Bibliografia Summary Indice
Impiego delle benzodiazepine e degli SSRI
nel trattamento del Disturbo da Panico
Use of benzodiazepines in the treatment of Panic Disorders
1 Nutt D. Neurobiological mechanisms in gcneralised anxiety disorder.
J Clin Psychiatry 2001;62:22-7.
2 Roy-Byrne PP, Cowley DS, Greenblat DJ, Shader RI, Hommer D. Reduced benzodiazepine sensitivity in panic disorder, Arch Gen Psychiatry 1990,47:534-8.
3 Malizia AL, Cunningham VJ, Beli CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA (A)-benzodiazepine receptor binding in panic disorder. preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998;55:715-20.
4 Ballenger JC, Burrows GD, DuPont Jr RL, Lesser IM, Noyes R Jr, Pecknold JC, et al. Alprazolam in panic disorder and agoraphobia. results from a multicenter trial. I. Effìcacy in short-term treatment. Arch Gen Psychiatry 1988;45:413-22.
5 Cross-National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder: comparative effìcacy of alprazolam, imipramine, and placebo. Br J Psychiatry 1992;160:191-202.
6 Uhlenhuth EH, Matuzas W, Glass RM, Easton C. Response of panic disorder to fìxed doses of alprazolam or imipramine. J Affect Disord 1989;17:261-70.
7 Schweizer E, Pattcrson W, Rickels K, Rosenthal M. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993a;150:1210-5.
8 Munjack DJ, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, et al. Alprazolam, propranolol and placebo in the treatment of panic disorder and agoraphobia with panic attack. J Clin Psychopharmacol 1989;9:22-7.
9 Andersch S, Rosenberg NK, Kullingsjo H, Ottosson JO, Bech P, Bruun-Hansen J, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatrica Scandinavica 1991;365:18-27.
10 Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg and placebo in panic disorder. J Clin Psychopharmacol 1992;12:96-103.
11 Curtis GC, Massana J, Udina C, Ayuso JL, Cassano GB, Perugi G. Maintenance therapy of panic disorder. J Psychiatr Res 1993;27:127-42.
12 Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment or panic disorder. I. Results of a prospective, placebo-controlled, comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993b;50:51-60.
13 The Clonazepam Panic Disorder Dose-Response Study Group, Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose response study of efficacy, safety, and discontinuance. J Clin Psychopharmacol 1997;17:390-400.
14 Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs G, Herman JB, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69-76.
15 Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G. Clonazepam in the treatment of panic-disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychiatry 1994;14:111-8.
16 Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990;23:90-3.
17 Charney DS, Woods SW. Benzodiazepine treatment of panic disorder – a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989;50:418-23.
18 Noyes R Jr, Burrows GD, Reich JH, Judd F, Garvey MJ Norman TR, et al. Diazepam versus alprazo]am for the treatment of panic disorder. J Clin Psychiatry 1996;57:349-55.
19 Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS. Effect of alprazolam and diazepam on anxiety and panic attacks i panic disorder: a controlled study. J Clin Psychiatry 1986;47:458-60.
20 Noyes R Jr, DuPont RL, Pecknold JC, Rubin RT, Swinson RP, Ballenger JC, et al. Alprazolam in panic disorder a agoraphobia. results from a multicenter trial. II. Paticnt acceptance, side eftects, and safety. Arch Gen Psychiatry 1988;45:423-8.
21 Pecknold J, Luthe L, Munjack D, Alexander P. A double-blind, placebo-controlIed, multicentre study with alprazolam and extendedrelease alprazolam in the treatment of panic disorder. J Clin Psychopharmacology 1994;14:314-21.
22 Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998;352:1331-1336.
23 Noyes R, Clancey J, Coryell WH, Crowe RR, Chaudhry DR, Domingo DV. A withdrawal syndrome after abrupt discontinuation of alprazolam. Am J Psychiatry 1985;142:11,4-116.
24 Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III discontinuation effects. Arch Gen Psychiatry 1988;45:429-36.
25 Ballenger JC. Long-term pharmacologic treatment of panic disorder. J Clin Psychiatry 1991;52:18-23.
26 Ballenger JC. Medication discontinuation in panic disorder. J Clin Psychiatry 1992;53:26-31.
27 Pecknold JC. Discontinuation reactions to alprazolam in panic disorder. J Psychiatr Res 1993;27:155-70.
28 Hallfors DD, Saxe L. The dependence potential of short half-life benzodiazepines: a meta-analysis. Am J Public Health 1993;83:1300-4.
29 Salzman C. Benzodiazepine treatment of panic and agoraphobic symptoms: use, dcpendence, toxicity, abuse. J Psychiatr Res 1993;27:97-110.
30 Toni C, Perugi G, Frare F, Mata B, Vitale B, Mengali F, et al. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Parmachopsychiatry 2000;33:121-31.
31 Kahn RS, Wetzler S, van Praag HM, Asnis GM, Strauman T. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res 1988;25:101-4.
32 Targum SD. Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biological Psychiatry 1990;28:21-34.
33 den Boer JA, Westenberg HG. erotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 1990;102:85-94.
34 Deakin JFW, Graeff FG. Critique. 5-HT and mechanisms of defence. J Psychpharmacol 1991;5:305-15.
35 Tork I, Hornung JP. Raphe nuclei and the serotonergic system. In: Paxinos G, ed. The Human Nervous System. San Diego: Academic Press 1990:1001-22.
36 Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfìeld HJ Jr. The antidepressants ftuoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implication. Brain Res 1992;572:117-25.
37 Gorman JM, Kent JM, Sullivan GM, Coplan JD Neuro anatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505.
38 Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fìxed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. American J Psychiatry 1998a;155:36-42.
39 Oehrberg S, Christiansen PE, Behnke K, Borup AL, Soegaard SJ, Calberg H, et al. Paroxetine in the treatment of panic disorder, A randomised, doubleblind, placebo-controlled study. Br J Psychiatry 1995;167:374-9.
40 The Collaborative Paroxetine Panic Study Investigators, Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica 1997b;95:153-60.
41 Bakker A, van Dyck R, Spjnhoven P, van Balkom AJ. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry 1999;60:831-8.
42 The Collaborative Paroxetine Panic Study Investigators, Lecrubier Y, Bakker A, Dunbar G, Judge R. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica 1997a;95 :145-152.
43 Judge R, Steiner M. The long-term effìcacy and paroxetine in panic disorder. Eur Neuropsychopharmacol 1996;6:207.
44 Pecknold JC, Luthe L, Iny L, Ramdoyal D. Fluoxetine in panic disorder pharmacologic and tritiated platelet imipramine and paroxetine binding study J Psychiatry Neurosci 1995;2:193-8.
45 Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB Fyer MR, Davies SO, Klein DF An open trial oj fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987;7:329-32.
46 The Fluoxetine Panic Disorder Study Group, Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry 1998;155:1570-7.
47 The International Panic Disorder Study Group, Tiller JWG, Bouwer C. Moclobemide and ftuoxetine for panic disorder. Eur Arch Psychiatry Clin Neurosci 1999;249:7-10.
48 Tiffon L, Coplan JD, Papp LA. Augmentation strategies with TCA or fluoxetine treatment in seven partially responsive PD patients. J Clin Psychiatry 1994;55:66-79.
49 Altamura AC, Mannu P. Trattamenti psicofarmacologici combinati nel DAP. In: Pancheri P, ed. Il punto su: Terapia del disturbo di panico. Firenze: Scientific Press 1997:157-4.
50 The Fluoxetine Panic Disorder Study Group, Michelson R, Pollack M, Lydiard RB, Tamura R, Tepner R, Tollefson G. Continuing treatment of panic disorder after acute response randomised, placebo-controlled trial with fluoxetine. Br J Psychiatry 1999;174:213-8.
51 Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, Klein DF. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-21.
52 Emmanuel NP, Ware MR, Brawman-Mintzer O, Ballenger JC, Lydiard RB. Once-weekly dosing of fluoxetine in the maint, nance of remission in panic disorder. J Clin Psychiatry 1999;60:299-301.
53 Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;544:146-9.
54 Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321-6.
55 Hoehn-Saric R, Fawcett J, Munjack DJ, Roy-Byrne PP. A multicentre, double blind, placeho-controlled study of fluvoxamine in the treatment of panic disorder. Neuropsychopharmacol 1994;10:38-53.
56 Nair NPV, Bakish D, Saxena B, Amin M, Schwartz G, West, TEG. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety 1996;2:192-8
57 Sandmann J, Lorch B, Bandelow B, Hartter S, Winter P, Hiemke C, Benkert O. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry 1998;31:117-21.
58 Holland RL, Fawcett J, Hoehn-Saric R, Munjack DJ, Roy-Byme PP. Long-term treatment of panic disorder with ftuvoxamine in outpatients who had completed double blind studies. Neuropsychopharmacol 1994;10:38-55.
59 Gorman J, Wolkow R. Sertraline as a treatment for panic disorder. Neuropsychopharrnacol 1994;10:117-75.
60 DuBoff E, England D, Ferguson JM. Double-blind comparison in three fixed doses of sertraline and placebo in patients with panic disorder. European Neuropsychopharmacol 1995;5:287.
61 Wolkow R, Apter J, Clayton A. Double-blind flexible-dose study of sertraline and placebo in patients with panic disorder. Eur Neuropsychopharmacolol 1996;6:113-9.
62 Baumel B, Bielski J, Carman J. Double-blind comparison of sertraline and placebo in patients with panic disorder. Eur Neuropsychopharmacol 1996;6:112-3.
63 Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C. Sertraline in the treatment of panic disorder. Br J Psychiatry 1998;73:54-60.
64 Sheikh JI, Londborg P, Clary CM, Fayyad R. The effìcacy of sertraline in panic disorder: combined results from two fìxed-dose studies. Intern Clin Psychopharmacol 2000;15:335-42.
65 Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder. a double-blind multicenter trial. Am J Psychiatry 1998;155:1189-95.
66 Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R. Sertraline in the treatment of panic disorder. Arch Gen Psychiatry 1998;55:1010-6.
67 Rapaport MH, Wolkow RM, Clary C. Methodologies and outcomes trom the sertraline multicenter flexible-dose trials. Psychopharmacol Bull 1998;34:183-9.
68 Pollack MH, Rapaport MH, Clary CM, Mardeikian J, Wolkow R. Sertraline treatment of PD: response in patients at risk for poor outcame.
J Clin Psychiatry 2000;61:922-7.
69 Rapaport MH, Wolkow RM, Rubin A, Hackett E, Pollack M, Ota KY. Sertraline treatment of panic disorder: results of a long term study. Acta Psychiatrica Scandinavica 2001;104:289-98.
70 Rapaport MH, Pollack M, Wolkow RM, Mardeikian J, Clary CM. Is placebo response the same as drug resposnse in panic disorder? Am J Psychiatry 2000;157:1014-6.
71 Wade AG, Lepola U, Koponen J, Pedersen V, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry 1997;170:549-53.
72 Lepola UM, Wade AG, Leinoncn EV, Kopenen HJ, Frazer J, Sjodin L, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998;59:528-34.
73 Leinonen E, Lepola U, Koponen H, Turtonen J, Wade A, Lehto H. Citalopram controls phobic symptoms in patients with panic disorder. randomized controlled trial. J Psych Neurosci 2000;25:24-32.
74 Humble M, Wistedt B. Serotonin, panic disorder and agoraphobia. short-term and long-term efficacy of citalopram in panic disorders. Intern Clin Psychopharmacol 1992;6:21-39.
75 Coplan JD, Pine DS, Papp LA, Gorman JM. An algorithm-oriented treatment approach for panic disorder. Psychiatric Ann 1996;264:192-201.
76 Mavassakalian M, Perel J. Imipramine in the treatment of agoraphobia: dose response relationships. Am J Psychiatry 1985;142:1032-6.
77 Cassano GB, Toni C, Musetti L. Treatment of Panic Disorder. In: Biggio G, Concas A, Costa E, eds. GABAergic Synaptic Transmission. New York: Raven Press 1992:449-60.
78 Noyes R Jr, Clancey J, Woodman C, Holt C, Suelzer M, Christiansen J, et al. Environmental factors related to the outcome of panic disorder. A seven-year follow-up study. J Nerv Mental Dis 1993;181:529-38.
79 Keller MB, Yonkers KA, Warshaw MG, Pratt LA, Gollan JK, Massion AO, et al. Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up. J Nerv Mental Dis 1993;182:290-6.
80 Faravelli C, Paterniti S, Scarpato. A 5-Year Prospective, Naturalistic Follow-up Study of Panic Disorder. Compr Psychiatry 1995;36:271-7.
81 McKenzie LJ, Risch SC. Fibrocystic breast disease following treatment with SSRIs. Am J Psychiatry 1995;1:152-3.
82 Holland RL. Fluvoxamine in panic disorder: after discontinuation? Neuropsychopharmacol 1994;10:102.
83 Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50.
84 Roy-Byrne PP, Clary CM, Miceli RJ, Colucci SV, Xu Y, Grudzinski AM. The effect of SSRI treatment of Panic Disorder on emergency room and laboratoty resource utilization. J Clin Psychiatry 2001;62:678-82.